Saltar al contenido
MilliporeSigma

T4580

Sigma-Aldrich

Tiludronate disodium salt hydrate

≥98% (HPLC)

Sinónimos:

Skelid, Tiludronic acid disodium, [[(4-Chlorophenyl)thio]methylene]bisphosphonic acid disodium salt hydrate

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización

Seleccione un Tamaño

10 MG
$86.73
50 MG
$344.00

$86.73

Precio de catálogo$91.30Ahorre 5 %
Web-Only Promotion

Disponible para envío el08 de abril de 2025Detalles


Solicitar un pedido a granel

Seleccione un Tamaño

Cambiar Vistas
10 MG
$86.73
50 MG
$344.00

About This Item

Fórmula empírica (notación de Hill):
C7H7ClNa2O6P2S · xH2O
Número de CAS:
Peso molecular:
362.57 (anhydrous basis)
Número MDL:
Código UNSPSC:
12352200
ID de la sustancia en PubChem:
NACRES:
NA.77

$86.73

Precio de catálogo$91.30Ahorre 5 %
Web-Only Promotion

Disponible para envío el08 de abril de 2025Detalles


Solicitar un pedido a granel

Ensayo

≥98% (HPLC)

Formulario

powder

condiciones de almacenamiento

desiccated

color

white to off-white

solubilidad

H2O: >10 mg/mL, clear

emisor

Sanofi Aventis

cadena SMILES

O.[Na+].[Na+].OP([O-])(=O)C(Sc1ccc(Cl)cc1)P(O)([O-])=O

InChI

1S/C7H9ClO6P2S.2Na.H2O/c8-5-1-3-6(4-2-5)17-7(15(9,10)11)16(12,13)14;;;/h1-4,7H,(H2,9,10,11)(H2,12,13,14);;;1H2/q;2*+1;/p-2

Clave InChI

SZVJRJRMQCKFON-UHFFFAOYSA-L

Acciones bioquímicas o fisiológicas

Tiludronate is a bisphosphonate bone resorption inhibitor. Tiludronate inhibits protein-tyrosine-phosphatase, leading to detachment of osteoclasts from the bone surface. It also inhibits the osteoclastic proton pump and is used to treat Paget′s disease.

Características y beneficios

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Nota de preparación

Tiludronate disodium salt hydrate is soluble in DMSO at a concentration that is greater than or equal to 10 mg/ml.

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable


Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Philippe Orcel et al.
Presse medicale (Paris, France : 1983), 34(8), 612-616 (2005-06-21)
Bisphosphonates, potent anti-osteoclastic agents, are nowadays the first-line therapy for Paget's disease of bone. Solid evidence about efficacy and the risk/benefit ratio favor tiludronate and risedronate for oral administration and pamidronate for intravenous administration. Treatment is always intermittent, with the
Catherine Delguste et al.
Canadian journal of veterinary research = Revue canadienne de recherche veterinaire, 75(2), 128-133 (2011-07-07)
This study assessed the feasibility of measuring tiludronate in horses using a minimally invasive bone biopsy technique. Eight horses were treated with intravenous (IV) tiludronate [1 mg/kg bodyweight (BW)], either once (n = 4) or twice, 28 d apart (n
M R Gough et al.
Equine veterinary journal, 42(5), 381-387 (2010-07-20)
Tiludronate regulates bone remodelling through a decrease of the resorptive process and should therefore ameliorate the remodelling processes active in osteoarthritis of the distal tarsal joints ('bone spavin') and alleviate pain associated with abnormal bone lysis. To confirm the efficacy
Maxim Moreau et al.
Arthritis research & therapy, 13(3), R98-R98 (2011-06-23)
The aim of this prospective, randomized, controlled, double-blind study was to evaluate the effects of tiludronate (TLN), a bisphosphonate, on structural, biochemical and molecular changes and function in an experimental dog model of osteoarthritis (OA). Baseline values were established the
Deepali D Deshmukh et al.
Drug delivery, 17(3), 145-151 (2010-02-09)
The efficacy of n-lauryl-beta-D-maltopyranoside, (dodecylmaltoside, DDM) as a permeability-enhancer for tiludronate and cromolyn (BCS Class III, water-soluble compounds with oral bioavailability < 5%) was evaluated in Caco-2 cell monolayers and rat intestinal sacs. In Caco-2 cells samples were collected over

Questions

Reviews

No rating value

Active Filters

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico